Try our beta test site
102 studies found for:    Open Studies | niaid
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | niaid
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Not yet recruiting Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants
Condition: HIV Infections
Interventions: Drug: Dolutegravir;   Drug: Emtricitabine/tenofovir alafenamide;   Drug: Emtricitabine/tenofovir disoproxil fumarate;   Drug: Efavirenz/emtricitabine/tenofovir disoproxil fumarate
2 Recruiting Etiology of Eczema Herpeticum (EH)
Condition: Eczema Herpeticum
Intervention:
3 Recruiting Safety and Immune Response to a Clade C DNA HIV Vaccine
Condition: HIV Infections
Interventions: Biological: DNA-HIV-PT123 vaccine;   Biological: Protein/MF59 vaccine;   Biological: Placebo
4 Recruiting Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa
Condition: HIV Infections
Interventions: Biological: ALVAC-HIV (vCP2438);   Biological: Bivalent Subtype C gp120/MF59;   Biological: Placebo
5 Not yet recruiting Safety and Immunogenicity of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant
Condition: Influenza A Virus, H7N9 Subtype
Interventions: Biological: H7N9 pLAIV;   Biological: H7N9 pIIV;   Biological: AS03 adjuvant
6 Recruiting Evaluating the Infectivity, Safety, and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants and Children 6 to 24 Months of Age
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: RSV LID ΔM2-2 1030s vaccine;   Biological: Placebo
7 Recruiting Safety and Effectiveness of a Seasonal Live Attenuated Influenza Vaccine in a Human Challenge Model of Infection With Wild-type (wt) Influenza A/California/2009 (H1N1)-Like Virus
Condition: Influenza, Human
Interventions: Biological: Seasonal LAIV;   Biological: Placebo;   Biological: Wild-type A/California/2009-like Influenza Virus
8 Recruiting Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: DNA-HIV-PT123 vaccine;   Biological: Bivalent Subtype C gp120/MF59 vaccine;   Biological: Bivalent Subtype C gp120/AS01B vaccine;   Biological: Placebo
9 Not yet recruiting Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in HIV-Infected and HIV-Uninfected Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis
Conditions: Tuberculosis;   HIV Infections
Intervention: Drug: Bedaquiline
10 Not yet recruiting Novel Mobile Device Application to Improve Adherence
Conditions: Pediatric Heart Transplant Recipients;   Pediatric Cardiac Transplantation;   Pediatric Heart Transplantation
Interventions: Device: TPP;   Other: Control Group
11 Recruiting Post‐Traumatic Stress Symptoms (PTSS) in Transplant Recipients
Conditions: Solid Organ Transplant Recipients;   Parent(s)/Guardian of Referenced Transplant Recipients
Intervention: Other: Assessment of adherence, mental health, behavioral, quality of life and biological constructs
12 Recruiting Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants 6 to 24 Months of Age
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: RSV LID cp ΔM2-2 Vaccine;   Biological: Placebo
13 Not yet recruiting Evaluating the Safety and Immunogenicity of a Live Attenuated Virus Vaccine to Prevent Influenza H3N2v Disease
Condition: Influenza
Interventions: Biological: H3N2v MN 2010/AA ca live attenuated influenza vaccine (LAIV);   Biological: H3N2v inactivated subvirion influenza vaccine;   Biological: Placebo
14 Not yet recruiting Evaluating the Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TetraVax-DV) TV005 in Flavivirus-Naive Adults 50 to 70 Years of Age
Condition: Dengue
Interventions: Biological: TetraVax-DV TV005;   Biological: Placebo
15 Not yet recruiting Partnership for Research on Ebola VACcinations
Condition: Ebola Virus Disease
Interventions: Biological: Ad26.ZEBOV;   Biological: MVA-BN-Filo;   Biological: rVSVΔG-ZEBOV-GP;   Biological: Placebo;   Biological: rVSV boost
16 Recruiting Evaluating the Safety and Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TV005 to Protect Against Infection With rDEN3Δ30
Condition: Dengue
Interventions: Biological: TetraVax-DV-TV005;   Biological: rDEN3Δ30;   Biological: Placebo
17 Not yet recruiting Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205
Condition: HIV Infections
Interventions: Biological: MVA/HIV62B vaccine;   Biological: AIDSVAX B/E vaccine;   Biological: Placebo
18 Not yet recruiting Evaluating the Safety, Pharmacokinetics, and Anti-Viral Activity of VRC01 and VRC01LS in the Serum and Mucosa of Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: VRC01;   Biological: VRC01LS
19 Not yet recruiting Evaluating the Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection
Condition: HIV Infections
Intervention: Drug: Maraviroc
20 Recruiting A Cohort Study of Operationally Tolerant Allograft Recipients
Conditions: Kidney Transplant;   Liver Transplant
Intervention: Procedure: Blood Draw

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.